Pathological gambling in Parkinson's disease. A comprehensive review  by Santangelo, Gabriella et al.
at SciVerse ScienceDirect
Parkinsonism and Related Disorders 19 (2013) 645e653Contents lists availableEditor’s comment: Pathologic gambling in Parkinson’s disease recently has become more widely recognized as a possible complication of
dopamine agonist therapy. It is a class speciﬁc effect and not necessarily related to any particular dopamine agonist. It usually occurs in
younger males, but it also may develop in patients with earlier symptomatic disease onset, in those with a prior history of alcohol and/or
substance abuse, or in those who possess personality traits characterized by impulsivity. The ﬁrst line of therapy usually is a dose reduction
or discontinuation of the dopamine agonist. Pathologic gambling also may occur in patients on levodopa monotherapy, but this is less
frequent. In this review article, Gabriella Santangelo and her colleagues provide a comprehensive analysis of the prevalence of pathologic
gambling and the associated clinical, behavioral, and cognitive features of this complication. Genetic susceptibility and possible therapeutic
management also are addressed, as are the potential neuro-anatomical and functional correlates of pathological gambling.
Zbigniew K. Wszolek, Co-Editor in Chief, Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Parkinsonism and Related Disorders
journal homepage: www.elsevier .com/locate/parkreldisReviewPathological gambling in Parkinson’s disease. A comprehensive
review
Gabriella Santangelo a,b, Paolo Barone c,**, Luigi Trojano a,*, Carmine Vitale b,d
aNeuropsychology Laboratory, Department of Psychology, Second University of Naples, Caserta, Italy
b Institute of Diagnosis and Care “Hermitage-Capodimonte”, Naples, Italy
cNeurodegenerative Diseases Center, University of Salerno, Salerno, Italy
dUniversity of Naples “Parthenope”, Naples, Italya r t i c l e i n f o
Article history:
Received 16 September 2012
Received in revised form
7 February 2013





Cognitive functions* Corresponding author. Department of Psychology,
viale Ellittico Complesso Universitario, 81100 Caserta,
** Corresponding author. Tel.: þ39 (0)89 672328.
E-mail addresses: gabriella.santangelo@unina2.it
unisa.it (P. Barone), luigi.trojano@unina2.it (L. Trojano
1353-8020  2013 Elsevier Ltd.
http://dx.doi.org/10.1016/j.parkreldis.2013.02.007
Open access under CC Ba b s t r a c t
Pathological gambling (PG) and other Impulse Control Disorders (ICDs), such as hypersexuality,
compulsive eating and buying, are often reported in Parkinson’s disease (PD). The prevalence of PG is
2.2%e7% in treated PD patients, which is higher than the background population rate. As other non
motor symptoms in PD, PG is frequently under-reported by patients and caregivers and may be
under-recognized by the treating physicians.
Factors associated with PG include male sex, younger age or younger age at PD onset, personal or
family history of substance abuse or ICD, a personality proﬁle characterized by impulsiveness, and
treatment with dopamine agonists (DA) more than with levodopa (L-dopa). The DA effect seems to be a
class effect and not speciﬁc for any DA.
Neurofunctional studies suggest that medication-induced downregulation of frontostriatal connec-
tions and upregulation of striatum might combine to induce impulsive behavior. A dysfunction of fronto-
subcortical circuits in PD patients with PG is also supported by neuropsychological ﬁndings of impaired
executive control and monitoring abilities.
Management of ICDs in PD is complex, and until now only discontinuation and/or tapering of DA treat-
ment seemtobe aneffectivemanagement strategy for ICDs inPD. There is noempirical evidence supporting
the use of psychiatric drugs for PG such as antipsychotics and antidepressants. Data regarding the effect of
deep brain stimulation (DBS), particularly of subthalamic nucleus, on PG and ICDs in PD are still limited and
sometimes conﬂicting since improvement of PG or new onset of PG after surgery have been reported.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Second University of Naples,




Pathological gambling (PG) is a behavioral disorder character-
ized by persistent and recurrent maladaptive gambling that can
have devastating psychosocial consequences for the person
involved and her/his family [1]. Point and lifetime prevalence rates
G. Santangelo et al. / Parkinsonism and Related Disorders 19 (2013) 645e653646of PG in general population are reported to be as high as 1.4% and
5.1%, respectively, but they seem to increase progressively with the
spread of legalized gambling [2].
PG is considered as an impulse control disorder (ICD) that com-
bines impulsive and compulsive features, namely repetitive gambling
and impaired inhibition of this negative behavior [3]. Neuroimaging
andneuropsychological studies foundanassociationbetweenPGand
abnormalities in the prefrontal cortex and subcortico-cortical net-
works projecting to the frontal cortex [4e6]. Current neurobiological
research highlighted both an abnormal functioning of mesolimbic
structures and an altered neurotransmitter regulation of the ‘reward
pathways’ in the brain of pathological gamblers [4], particularlyof the
neurotransmitter dopamine.
As it will be described below, PG is largely more frequent in
patients affected by Parkinson’s disease (PD) than in the general
population. Alteration of dopaminergic transmission in both PG
and PD might support common pathophysiologic mechanisms and
some clinical overlap of the two conditions. Traditionally, PG has
been considered as a side effect of dopamine agonists (DA) treat-
ment in PD [7e9]. However, since only a small proportion of pa-
tients treated with DA develop PG and/or other ICDs, we will argue
that DA medication can trigger these non motor symptoms in PD
patients with speciﬁc individual predisposing factors.
In the present paper we will offer an overview of the most
recent advances in the study of clinical, neuropsychological,
behavioral, neurofunctional and genetic correlates of PG in PD.
Finally, the management of PG in PD will also be reviewed.
2. Prevalence of PG in PD
The prospective PG prevalence (either current or anytime during
PD) in a tertiary PD clinic has been reported to vary from 2.2% to 7%
(Table 1); such percentages are higher than those reported in general
population (see above) and become also higher if one considers
“problem gambling” (not clinically relevant gambling behavior). As
evident inTable 1, prevalence rates in Caucasian samples [7e13] tend
to be higher than those reported in Asian countries [14e17]. This
divergence might depend on cultural and ethnic differences [14]
(e.g., reluctance to admit presence of PG, availability of legalized
gambling, lower DA usage in Asian countries than in Caucasian
populations), methodological differences (e.g., different diagnostic
criteria or assessment methods), or genetic differences (e.g., variable
occurrence of genetic polymorphisms among Caucasians and
Asians). However, signiﬁcant discrepancies in prevalence rates of
problem/pathological gambling can be found even between twoTable 1
Results of prevalence studies in PD patients with PG.
Authors N. patients Population Prevalence (%)
Lu et al., 2006 [12] 200 Tertiary PD clinics 7 (PG alone)
Grosset et al., 2006 [13] 388 Tertiary PD clinics 4.4 (PG alone)
Voon et al., 2006 [8] 297 Tertiary PD clinics 3.4 (PG alone)
Avanzi et al., 2006 [10] 98 Tertiary PD clinics 6.1 (PG alone)
Weintraub et al., 2006 [9] 272 Tertiary PD clinics 2.2 (active case
Crockford et al., 2008 [11] 140 Tertiary PD clinics 9.8 (problem g
Weintraub et al., 2010 [7] 3090 Tertiary PD clinics 5 (problem and
Antonini et al., 2011 [24] 103 Tertiary PD clinics 0.9 (problem/p
Weintraub et al., 2013 [25] 168 Tertiary PD clinics 1.2 (problem/p
Asian countries
Fan et al., 2009 [15] 400 Tertiary PD clinics 0.32 (PG alone)
Lee et al., 2010 [17] 1167 Tertiary PD clinics 1.3 (PG alone)
Chiang et al., 2012 [14] 278 Tertiary PD clinics 1.49 (PG alone)
Auyeung et al., 2011 [16] 213 Tertiary PD clinics 6.1 (PG alone)
SOGS ¼ South Oaks Gambling Screen; MIDI ¼ Minnesota Impulsive Disorders Interview
Compulsive Disorders in Parkinson’s Disease.Caucasians populations (i.e., US and Canadian patients; [7]), thus
highlighting that differences among PD populations have not been
fully elucidated.
Apart from ethnic and cultural factors, one source for variability
in prevalence rates of PG in PD seems to be related tomeasures used
for screening. As shown in Table 1, prevalence rates tend to be lower
when diagnosis rests on self-administered questionnaires [8] than
on informant-based interviews [9,10,12,13,18], as many patients
have reduced insight into the social consequences of their behavior
or conceal it from their families because of shame or denial [19]. Use
of speciﬁcallydevisedandvalidateddiagnostic tools administered to
both patients and caregivers can likely reduce possible underesti-
mation of PG, and of other ICDs in PD. Two such questionnaires have
been developed in recent years: the Questionnaire for Impulsive-
Compulsive Disorders in Parkinson’s Disease (QUIP) [20] and the
Parkinson’s diseaseDopamineDysregulation Syndrome-Patient and
Caregiver (DDS-PC) inventory [21]. Both screening tools have good
clinometric properties. The QUIP has been proved to be a sensitive
instrument for detection of ICD whether completed by a patient or
informant [22]. Agreement between patient- and informant-
reporting of any ICD behaviors on the QUIP was moderate to fair
for individual ICDs, but was high for PG [23].
It is important to underlinehere that the assessmentofprevalence
rates during the disease course will likely provide valuable cues for
comprehending the genesis of PG and other ICDs in PD. Two recent
studies reported low prevalence of PG among newly diagnosed PD
patients with rates (0.9% [24] and 1.2% [25]) similar to those reported
in general population, whereas prevalence of at least one ICD was
quite high (17.5% [24] and 20% [25]). Suchﬁndingswould suggest that
several factors contribute to development of ICDs in PD.
3. Clinical and behavioral features associated with PG in PD
In general population, older age, poor socioeconomic status,
mental disorders (e.g. manic and depressive disorders) [26] and
alcohol or substance use seem to be factors associated with
development of disordered gambling (for a recent review, see Ref.
[27]). Moreover, two personality traits seem to be associated with
PG: high impulsivity (the tendency to react to internal or external
stimuli with diminished regard to negative consequences of these
reactions [28]) and high novelty seeking (an individual’s tendency
toward excitement in response to new stimuli or cues for potential
rewards, leading to frequent exploratory activity in pursuit of such
experiences), which appears to be modulated by dopaminergic
transmission in the ventral striatum [29,30]. Finally, pathologicalTools
Face-to-face interviews
Semi-structured interview based on DSM-IV criteria
Modiﬁed SOGS
Interview based on DSMIV-TR; SOGS
s of PG) Modiﬁed MIDI
ambling: 3.6; PG: 5.7) CPGI
pathological gambling) Massachusetts gambling screen
athological PG) SOGS
athological PG) QUIP
Modiﬁed south oaks gambling screen (SOGS),
interview based on DSM-IV-TR criteria for PG
Minnesota impulsive disorders interview
Interview based on DSM-IV-TR criteria for PG
Structured screening questionnaire
; CPGI ¼ Canadian Problem Gambling Index; QUIP ¼ Questionnaire for Impulsive-
G. Santangelo et al. / Parkinsonism and Related Disorders 19 (2013) 645e653 647gamblers show high rates of other ICDs, particularly compulsive
buying, compulsive sexual behavior and intermittent explosive
disorder [31e33].
In PD patients, PG occurs in relation to DA and L-dopa treatment
(see below the “PD therapy and management of PG” section), but
some of the abovementioned factors seem to be associated to
development of PG. In particular, male gender, young age at onset of
PD, previous personal or family history of gambling problems,
alcohol and/or substance abuse have been found to increase risk for
developing PG [28,34e40]. In a recent prospective study, patient-
speciﬁc risk factors for ICDs including greater usage of caffeine
and cigarettes, motor complications, and higher peak dopamine
agonist dosage have been identiﬁed [41].
Moreover in PD patients (see Table 2), as in the general popu-
lation, novelty seeking and high impulsivity were associated with
PG [36,38,39,42,43]. In particular, Voon et al. [43] reported that PG
patients had greater impulsive choice with higher reward magni-
tudes reﬂecting the tendency toward immediate over delayed
gratiﬁcation.
Some studies tend to show higher aggressiveness, anxiety, irri-
tability, disinhibition, obsessive compulsive features, medication-
induced hypomania or mania in PD pathological gamblers than in
non-gamblers [42e44], but these ﬁndings have not been conﬁrmed
by other studies [45,46]. As in general population, in PD patients
too (Table 2) PG often co-occurs with hypersexuality (HS),
compulsive shopping (CS), compulsive eating (CE), and Internet
addiction [44,46,47]. Since PG and CS share more severe psycho-
logical aspects (greater anxiety, compulsive features, and novelty
seeking) than other ICDs (CE and HS), it has been suggested that
differences between these subtypes of ICDs (PG and CS versus CE
and HS) may reﬂect differences between intrinsic (e.g., food, sex)
and learned (e.g., money) rewards [36,43], with likely different
neural correlates, yet to be explored in neuroimaging studies.
In summary, results from recent studies evidenced that devel-
opment of PG in PD patients under DA treatment is frequently
associated with individual features similar to those reported in the
general population, including speciﬁc personality traits (mainly
novelty seeking and impulsivity). Also comorbidity of PG and other
ICDs seems to be similar in PD patients and general population, but
the relationships among clinical and behavioral aspects associated
with PG in PD seem to require further studies.Table 2
Results of behavioral studies in PD patients with PG.
Authors N. Patients Behavioral aspects
Voon et al., 2007 [42] 21 PD þ PG;
42 PDPG;
286 PDPG
BIS-11, TCI, SCID-I, BDI, AS, S
Santangelo et al., 2009 [45] 15 PD þ PG;
15 PDPG
HAM-D, SCID-I for mania
Siri et al., 2010 [44] 21 PD þ PG;
42 PDPG;
NPI; GDS
Rossi et al., 2009 [46] 7 PD þ PG;
13 PDPG
NPI, MADRS, ZuckermaneKu
Voon et al., 2011 [43] 54 PD þ PG;
282 PDPG
STAI-state, STAI-trait, GDS, B
novelty seeking exploratory,
impulsive, disorganized, imp
choice (DDT) K and large rew
BIS ¼ Barratt Impulsiveness Scale; TCI: Temperament and Character Inventory; SCID-I ¼
Inventory; HAM-D ¼ Hamilton Depression Rating Scale; NPI ¼ Neuropsychiatric Invent
Rating Scale; DDT ¼ Delay Discounting Task; K ¼ slope; PD þ PG ¼ PD patients with PG4. Cognitive impairments associated with PG in PD
In pathological gamblers not affected by PD some recent studies
have documented presence of frontal/executive dysfunctions
[33,48e53], and, in particular, impairments in decision-making
processes [54]. Decision-making connotes both the process of
choosing under ambiguous or risky situations and the optimal se-
lection in terms of rewarding or punishing outcomes among several
alternative courses of action [55]. Decision-making impairments,
independently from PG, have also been found in patients with focal
lesions in the prefrontal cortex, amygdala, striatum, insula and
parietal cortex [56,57].
Until now, few studies explored cognitive correlates of PG in PD
(Table 3). Santangelo et al. [45] found more severe frontal lobe
dysfunction, including alteration of cognitive ﬂexibility and set-
shifting, in non-demented PD patients with PG as compared with
PD patients without PG. A further neuropsychological study
comparing the cognitive proﬁles of PD patients affected by PG, HS,
or CE alone or in combination [47] revealed that PG patients are
generally less impaired on some frontal and memory tests than
patients with other single or combined ICDs. The presence of
frontal dysfunction in PD patients with PG has not been conﬁrmed
in two studies [42,44], in which however, demented patients were
not excluded and gamblers were signiﬁcantly younger than non-
gamblers.
The possible association between deﬁcits in decision making
and PG has been recently investigated in a small PD sample [46],
showing that PD patients with PG might have poorer decision-
making abilities than non gambler PD patients. When challenged
for ambiguous situations, PD gamblers selected disadvantageous
alternatives and had difﬁculties to shift to the more advantageous
ones, suggesting a dysfunction of both ventral medial pre-frontal
cortex (VMPFC) and amygdala-ventral striatum circuit. When
decision-making was required in conditions where outcome
probabilities were known or calculable, PD gamblers showed
normal decision-making [46]. These interesting observations merit
to be replicated in larger PD samples.
In summary, the studies on cognitive impairments associated to
PG suggest that, in both general population and PD patients,
compulsive and perseverative behaviors might reﬂect an impair-
ment in monitoring, controlling, and modifying negative behavior.Results
CID-I PD þ PG > PDPG on total score and planning
subscore of BIS-11, novelty seeking score of TCI;
SCID-I for personal or family history alcohol use
disorder and mania. No difference on BDI, AS and
SCID-I for anxiety disorder
No difference on all tools
PD þ PG > PDPG on disinhibition, irritability,
eating disorders subscales of NPI. No difference on
GDS and hallucinations, delusions, depression,
euphoria, sleep disorders, anxiety, apathy,
aberrant motor behavior subscales of NPI





PD þ PG > PDPG on STAI-state, novelty seeking
total score, impulsive, disorganized, Impulsive
choice (DDT) K and large reward. No difference
on GDS, STAI-trait, novelty seeking exploratory,
extravagant, BIS total
Structured Clinical Interview for DSM-IV Axis I Disorders; BDI ¼ Beck Depression
ory; GDS ¼ Geriatric Depression Scale; MADRS ¼ Montgomery-Asberg Depression
; PDPG ¼ PD patients without PG.
Table 3
Results of cognitive studies in PD patients with PG.
Authors N. Patients Cognitive tasks Results




Santangelo et al., 2009 [45] 15 PD þ PG;
15 PDPG
FAB, Phon-Fluency, TMT: B-A, WCST;
Sem-Fluency, Corsi’s Test, Verbal span,
RCPM, ROCF-copy; Memory: immediate
and delayed recall, ROCF-delayed recall
PD þ PG < PDPG on FAB, Phon-Fluency; TMT: B-A.
No difference on WCST, Sem-Fluency, Corsi’s Test,
Verbal span, RCPM, ROCF-copy, immediate and delayed
recall and ROCF-delayed recall
Siri et al., 2010 [44] 21 PD þ PG;
42 PDPG;
Phon-Fluency, Sem-Fluency, Attentive
Matrices, Digit Span, Corsi’s Test, FAB,
RCPM; Denomination, Memory:
immediate and delayed recall
PD þ PG > PDPG on Phon-Fluency and Sem-Fluency.
No difference on Attentive Matrices, Digit Span,
Corsi’s Test, FAB, RCPM, Denomination and Memory:
immediate recall and delayed recall
Rossi et al., 2009 [46] 7 PD þ PG;
13 PDPG
Addenbrooke’s Cognitive Examination,
FAB, WCST, Stroop Test, Go/No-Go task, SRL-RET
No difference on all tools
Vitale et al., 2011 [47] 14 PD þ PG;
14 PD-ICDs;
13 PD þ HS;
12 PD þ CE;
10 PD þ mICDs
TMT, ROCF-copy, WCST, Attentive
Matrices, Stroop Test, verbal long-term memory
PD þ PG < PD-ICDs on TMT, ROCF-copy.
No difference on WCST, Attentive Matrices,
Stroop Test, verbal long-term memory. PD þ PG >
PD þ HS, PD þ PG > PD þ CE, PD þ PG > PD þ mICDs
on verbal long-term memory.
PD þ PG > PD þ HS, PD þ PG > PD þ mICDs on
Stroop Test. No difference on TMT, ROCF-copy,
WCST, Attentive Matrices
FAB ¼ Frontal Assessment Battery; Phon-Fluency ¼ Phonological Fluency Task; TMT: B-A ¼ Trail Making Test: B-A; WCST ¼ Wisconsin Card Sorting Test; Sem-Fluency:
Semantic Fluency; RCPM ¼ Raven’s colored progressive matrices; ROCF ¼ Rey-Osterrieth complex ﬁgure test; SRL-RET ¼ Stimulus reward learning, reversal and extinc-
tion task; PD þ PG ¼ PD patients with Pathological GamblingG; PDPG ¼ PD patients without PG; PD þ HS ¼ PD patients with Hypersexuality; PD þ CE ¼ PD patients with
Compulsive Eating; PD þ mICDs ¼ PD patients with multiple ICDs.
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the onset and maintenance of PG [58].
5. Genetic susceptibility
The involvement of brain’s reward system in addictions made
the dopamine system genes the primary targets of candidate genes
for association studies on PG, but the possible role of other
neurotransmitter systems has been also explored [59].
In general population, early studies focused on the dopamine
receptor D2 (DRD2). The A1 allele of DRD2 Taq 1A is associated with
decreased receptor density in the striatum and with cocaine
addiction and PG [60e62]. Moreover, associations between dopa-
mine receptor D1 (DRD1) polymorphism with PG [63] and with
comorbid PG and alcohol dependence have been reported [64]. The
dopamine receptor D3 (DRD3), mainly distributed in the limbic
areas of the brain, displays a number of single nucleotide poly-
morphisms (SNPs), the most frequently studied of which is Ser9Gly
SNP [65,66]. This polymorphismhas not found to be associatedwith
PG [67]. As for the dopamine receptor D4 (DRD4), a polymorphism
in exon III has been reported to encode a receptorwith lower afﬁnity
for dopamine [68], and to be associated with impulsive personality
traits [69,70] and PG [71]. Moreover, in general population genetic
polymorphisms of DATand COMTseem to contribute to ICDs: COMTTable 4
Results of molecular genetic association studies in PD patients with PG.
Authors Sample
Subjects diagnosis Controls
Lee et al., 2009 [78] 404 PD patients (58 ICDþ; 346 ICD) 559 healthy
Vallelunga et al., 2012 [79] 41 PD-ICDþ patients 49 PD-ICD
Lee et al., 2012 [80] 404 PD patients (58 ICDþ; 346 ICD) 409 healthy
PD: Parkinson’s disease; ICDþ: Impulse Control Disorders positive (PG and other ICDs); I
Serotonin Transporter Gene; DRD3: Dopamine D3 Receptor; GRIN2B: glutamate N-meth
DAT: Dopamine transporter Gene; HTR2A: serotonin 2A receptor gene.Val158Met and a 40 base pairs variable number of tandem repeat
(VNTR) DAT polymorphism have been found to be associated with
alcohol dependence and drug abuse [72].
Dysfunctions of other neurotransmitter systems, such as the
serotoninergic system, may contribute to deﬁcient impulse control
and impulsive personality features [73]. The serotonin transporter
gene (5-HTTLPR) “S” allele has less transcriptional activity and has
been associated to both PG [74] and impulsivity [75] in general
population. Finally, also glutamate seems to participate in transi-
tion from reward learning to repetitive behaviors in drug addiction
[76]; glutamate levels within the nucleus accumbens seem to
mediate reward-seeking behavior [77].
In PD patients, only a few studies investigated the role of genetic
polymorphisms of the dopaminergic system in PG and other ICDs
(Table 4). Some relevant polymorphisms investigated in general
population have not been assessed in PD patients (i.e., DRD1 and
DRD4), whereas other polymorphisms have been assessed in PD
patients with PG or other ICDs without ﬁnding any signiﬁcant as-
sociation (i.e., DRD2 Taq 1A variants [78,79], genetic poly-
morphisms of DAT and COMT [77]). Notably, the homozygous
variant Ser9Gly (AA genotype) of DRD3 is possibly associated with
lower binding afﬁnity to dopamine and seemed to be associated
with two-fold increase in the risk of PG and ICDs in PD patients [78],
but not in general population.Polymorphism Results
subjects DRD2 Taq 1A No association
5-HTTLPR No association
DRD3 Ser9Gly Association with AA genotype
GRIN2B Association with CC genotype
patients DRD2 Taq 1A No association
COMT Val158Met No association
DAT1 (30 UTR 40 bp VNTR) No association
subjects HTR2A 102T > C Association with CT and TT genotype
CD: Impulse Control Disorders negative; DRD2: Dopamine D2 Receptor; 5HTTLPR:
yl-D-aspartate (NMDA) receptor, 2B subunit; COMT: catechol-O-methyltransferase;
G. Santangelo et al. / Parkinsonism and Related Disorders 19 (2013) 645e653 649As regards serotoninergic systems, the serotonin transporter
gene (5-HTTLPR) “S” allele has been shown to be more frequent in
PD patients with PG and ICDs, although neither dominant nor
recessive model revealed any associations [78]. More recently, a
genetic variant affecting serotonin 2A receptor (HTR2A) pathway
has been found to be associated with ICDs in PD patients receiving
dopamine replacement therapy, mainly under low-dopaminergic-
dose conditions [80].
Last, the CC genotype of the 2B subunit (GRIN2B) of the gluta-
mate N-methyl-D-aspartate (NMDA) receptor, mainly expressed in
the striatum [81], has been found to be more frequent in PD pa-
tients with PG and ICDs than in non-affected patients [78].
In synthesis, studies on genetic susceptibility for PG and ICDs in
PD patients are quite limited and often included a relatively small
number of patients (for a recent review, see Ref. [82]). Available
data seem to suggest an association of PG with DRD3 and not with
DRD2, differently from what reported in non-PD population, and
with polymorphisms of serotoninergic and glutamatergic path-
ways, but these results await to be conﬁrmed in further indepen-
dent studies on larger samples of PD patients.6. Neuro-anatomical and functional correlates in PG
Frontal lobes are involved in processing, integrating and inhib-
iting impulses received from the limbic system, striatum, temporal
lobes, and neocortical sensory regions [83e88]. In general terms,
prefrontal cortex can be considered as a cortical region mediating
‘top down’ regulation of subcortical (‘bottom up’) mechanisms of
reward and incentive [88]. Therefore, patients with frontal-striatal
pathways dysfunctions may have difﬁculties to inhibit unwanted
movements or thoughts, and may develop perseverative, compul-
sive and impulsive behaviors [89], such as PG [45]. Accordingly,
neuroimaging studies in pathological gamblers not affected by PD
revealed structural and functional abnormalities of frontal-striatal
pathways, in particular in the ventromedial prefrontal cortex and
cortico-basal-ganglionic-thalamic circuits [90e100].
In recent years, neuro-anatomical and functional correlates of
PG in PD patients have been explored by several studies [101e105]
(Table 5). Reported ﬁndings are not easy to summarize, also
because of the different methodological approaches employed, but
there is substantial convergence in highlighting that dysfunction of
orbitofrontal cortex, anterior cingulate cortex (ACC), amygdala,
insula and ventral striatum are often found in pathologicalTable 5
Results of neuroimaging studies in PD patients with PG.
Authors Methods Sample
Cilia et al., 2008 [101] TC99m SPECT 11 PD þ PG patien
Steeves et al., 2009 [102] [11C]Raclopride PET 7 PD þ PG patients
Cilia et al., 2011 [103] SPECT 15 PD þ PG patien
15 matched health
Jotsua et al., 2012 [104] [18F]F-Dopa PET 10 PD þ PG patien
Ray et al., 2012 [105] [11C]FLB-457 PET 7 PD þ PG patients
fMRI, functional Magnetic Resonance Imaging; PET, Positron Emission Tomography; SP
SPECT, Single Photon Emission Tomography; PG, Pathological gambling.gamblers. These cortical and subcortical structures are considered
to be part of a brain network implicated in decision making, risk
processing, and response inhibition; dysfunction of this network
has been found to be correlated with gambling severity in PD pa-
tients [103]. The evidence of a lack of “connectivity” within this
functional network, speciﬁcally a lack of correlation between ac-
tivity in the anterior ACC and the striatum, is consistent with pre-
vious neuropsychological ﬁndings [45,47] andwith the idea that PG
can arise from a speciﬁc impairment of shifting behaviors after
negative outcomes and perseverative risk-taking habits despite
self-destructive consequences.
Recent neurofunctional studies with different radiotracers pro-
vided new information about possible neural correlates of PG in PD
patients. The novel ﬁndings from these studies mainly relate to the
possibility that some cortical regions involved in the control of
behavior, such as medial orbitofrontal cortex [104] or anterior
cingulate cortex [105], may show dysfunctional activation, thus
suggesting that alteration of DA homeostasis might impact in-
dividuals’ vulnerability for impulsivity and modulate risk for
development of PG in PD.
Taken together, available ﬁndings seem to be consistentwith the
hypothesis that PG occurs in PD patients as a result of abnormal
reward-based learning processes and reduced inhibition of impul-
sive drives combined with dopamine overstimulation of meso-
corticolimbic pathways. Further prospective controlled studies in
larger cohorts are needed to investigate the predisposing factors for
development of PG in PD patients undergoing dopamine replace-
ment therapy.7. PD therapy and PG management
Numerous studies evidenced a strong association between DA
therapy and PG. This association has been ascribed to excessive
activation of the mesocorticolimbic dopaminergic system, which
under physiological conditions mediates the response to natural
rewards [28]. In PD patients, dopamine neurons projecting to the
dorsal striatum (putamen and dorsal caudate) are less severely
affected than those projecting to the ventral striatum (ventral
caudate and nucleus accumbens) [106]. This raises the possibility
that pharmacological restoration of dopamine neurotransmission
in the motor striatum leads to overstimulation of the limbic stria-
tum thus eliciting abnormal behaviors [107]. This difference in
dopamine levels between the dorsal and ventral striatum can alsoResults
ts; 40 matched PD controls Abnormal resting state overactivity in
orbitofrontal cortex, hippocampus,
amigdala, insula and ventral pallidum
in PD patients with PG
; 7 matched PD patients Increased striatal dopamine release
in PD þ PG patients
ts; 15 PDPG patients;
y controls
Decreased prefrontal cortex, cingulate,
insula, parahippocampal gyrus, and
striatal resting perfusion in PD þ PG
patients; Anterior Cingulate Cortex-Striatal
disconnection in PD þ PG patients
ts; 10 PDPG patients Increased monoaminergic activity in the
medial orbitofrontal cortex in PD þ PG
patients under dopaminergic treatment
; 7 PDPG patients Reduced [11C]FLB-457 midbrain binding
potential (BP) in PD with PG patients;
increased [11C]FLB-457 BP in the anterior
cingulate cortex in PD patients with PG
ECT, Single Photon Emission Computerized Tomography; PD, Parkinson’s Disease;
G. Santangelo et al. / Parkinsonism and Related Disorders 19 (2013) 645e653650account for the ﬁnding that L-Dopa, by its phasic stimulation of
dopamine receptors, improves performance on cognitive tasks
involving the dorsal striatum (e.g., working memory and task-set
switching), but worsens performance on test which depend on
the ventral striatum (e.g., reversal learning and Cambridge
Gambling Task) [108e110]. By contrast, tonic stimulation of dopa-
mine receptors with DA speciﬁcally desensitizes the reward mes-
ocorticolimbic system by preventing decreases in dopaminergic
transmission that occurs with negative feedback [111]. These ob-
servations ﬁt well with the increased risk to develop PG speciﬁcally
related to DA treatment in PD patients [7,8,112].
Another neurobiological factor that may contribute to meso-
corticolimbic overdosing is sensitization, which refers to an
increased effect of stimulant drugs with repeated administration
[113]. The dopamine D3 receptor may play a role in sensitization
and in the development of addictive syndromes in PD. DRD3 is
primarily expressed in the limbic system, and is upregulated in
response to levodopa treatment in animal models of PD [114].
Moreover, DRD3 appears to control the phasic, but not tonic, ac-
tivity of dopaminergic neurons whichmay be induced by novelty or
presentation of drug-conditioned cues in rodents [115e117]. Since
non ergot DA such as pramipexole and ropinirole have a high af-
ﬁnity for both D2 and D3 receptors and the stimulation of D3 re-
ceptors mediates activation of mesocorticolimbic reward system, it
is possible that abnormal expression of D3 receptors in ventral
striatum is associated with ICDs occurrence. These data seem to
converge on an important role for the D3 receptor in modulating
the physiologic and emotional experience of novelty, reward, and
risk assessment and likely explain the relatively higher rates of
pathological behaviors among patients taking DA.
An important review showed that PG in PD is associatedwith DA
therapy, as a class, in 98% of cases [40], although this ﬁndingmay be
confounded by factors such as higher rates of DA use in younger
patients [9,28]. Most authors reported a dose-dependent onset of
PG in PD patients treated with DA, with improvement or resolution
following DA tapering. Other reports referred to an “all-or-none”
phenomenon with complete resolution of PG after DA withdrawal
[37,118e120]. Although ICDs have been reported during treatment
with all DA, an analysis of the Food and Drug Administration
Adverse Event Reporting system database showed that 58% of 67
gambling reports are associated with pramipexole [121], likely
because of its high relative selectivity for DRD3.
While DA use is strongly associated with development of ICDs in
PD patients, levodopa in monotherapy is not [9,112], although it has
been suggested that L-dopa might play a role in priming these be-
haviors [122e125]. There are few reports implicating monoamine
oxidase-B inhibitors in PG, although these patients were already
taking other antiparkinsonian medication [29,126].
Data regarding the effect of deep brain stimulation (DBS) on PG
and ICDs in PD are still limited. Variable and sometimes conﬂicting
reports about PG in PD patients with DBS on subthalamic nucleus
(STN) have been published to date. A recent retrospective study
evidenced that only in a few (2 out of 7) PD patients ICDs resolved
after unilateral or bilateral STN DBS; therefore, the authors sug-
gested that clinicians should not consider unilateral or bilateral DBS
to be a solution to ICDs in PD [127]. In fact, the few reports of
positive outcome after STN DBS [128,129] might be likely related to
discontinuation of dopaminergic treatment after surgery, whereas
in other patients ICD were observed as a new onset phenomenon
after surgery [130,131]. Selective stimulation of the associative and
limbic region of the STN, and of surrounding related structures, has
also been reported to trigger or worsen non-motor side effects
[132e136].
Little is known about optimal management strategies of PD
patients with PG, as available evidence mainly came from openlabel studies and case reports [9,40,124,137]. Two long-term follow-
up studies [119,138] and further recent case reports [139e142],
however, suggested that discontinuation of DA treatment can
represent the ﬁrst line management strategy of ICDs, with full
remission or clinically signiﬁcant reduction of symptomatology.
Tapering DA treatment can be useful too, and only in patients who
do not tolerate tapering, replacement with other drugs (including L-
dopa, anticholinergics, catechol-O-methyltransferase inhibitors,
and monoamine-oxidase-B inhibitors) can be considered
[36,38,143]. Notably, a recent study [144] reported that 19% of pa-
tients who tapered DA treatment (one-third because of ICDs),
particularly those with higher peak DA doses and greater cumula-
tive DA exposure, developed a withdrawal syndrome. The Dopa-
mine Agonist Withdrawal Syndrome (DAWS) is characterized by
prominent psychiatric (e.g., anxiety, dysphoria, depression, agita-
tion) and autonomic (orthostatic hypotension, diaphoresis) mani-
festations, similarly to withdrawal syndromes observed with other
drugs (such as cocaine and amphetamines) stimulating meso-
corticolimbic dopaminergic pathways. Since DAWS can cause se-
vere, long-term psychosocial consequences, some authors
suggested to monitor patients with ICDs whenever DA are with-
drawn, and to taper DA as soon as ICDs develop [144].
Atypical antipsychotics [145e149] have been reported to reduce
PG in PD patients, but with variable degree of motor function
worsening. Antidepressants, mood stabilizers, and several psy-
chosocial interventions may also be beneﬁcial [145,146,149]. All
these strategies might be considered as secondary management
strategies for ICDs, but this issue should be further explored. Recent
preliminary studies with zonisamide and topiramate have shown
promising results in reducing gambling urges in PD [150,151].
Conﬂicting data have been reported regarding use of amantadine: it
proved to be beneﬁcial in 17 PD patients with PG, reducing or
abolishing gambling urges and hours spent gambling [152], but two
further studies and a case report have shown that amantadine is
associated with PG and other treatment-related behavioral disor-
ders [35,153,154]. Moreover, according to the recently published
MDS-EBM (Movement Disorders Society, Evidence BasedMedicine)
review update for treatment of non motor symptoms in PD, there is
insufﬁcient evidence for the efﬁcacy of amantadine for treatment of
PG in PD patients [155]. More recently, treatment of PG with opioid
antagonist naltrexone resulted in full remission of disorder in three
parkinsonians [156]. It has been proposed that the efﬁcacy of opioid
antagonists in the treatment of addictive disorders involves opioi-
dergic modulation of mesolimbic dopamine circuitry [157]. Further
work to deﬁne if opioid antagonists have beneﬁcial effects for PG
and also other ICDs could enhance treatment strategies.
8. Conclusions and future perspectives
PG can impair activities of daily living and have a strong nega-
tive impact on quality of life of patients and their families. The
largest prospective study on PD patients demonstrated that point
prevalence of PG can be as high as 5% [7], and nonetheless PG is still
frequently under-reported as many patients have reduced insight
into social consequences of their behavior. These data show how
much important is to screen PG using speciﬁcally devised and
validated diagnostic tools and to consider both patients’ and care-
givers’ reports. It is also important to take into account that, as in
general population, some risk factors can help to identify PD pa-
tients who are susceptible to develop PG during DA therapy. Clinical
factors associated with development of PG include young age at
disease onset, personal or family history of alcoholism, impulsive or
novelty-seeking personality, and prior history of ICDs.
The cognitive correlates of PG in PD have been poorly investi-
gated. As pathological gamblers without PD, non-demented PD
G. Santangelo et al. / Parkinsonism and Related Disorders 19 (2013) 645e653 651patients with PG showed more severe frontal lobe dysfunction,
including alteration of decision making, cognitive ﬂexibility and
set-shifting as compared with PD patients without PG. Also neu-
roimaging studies revealed some similarities in non-PD gamblers
and in PD patients with PG, pointing to abnormalities in the
ventromedial prefrontal cortex and in cortico-basal-ganglionic-
thalamic circuits. The alterations in the reward centers of the
brain suggest possible drug-induced overstimulation of less
affected mesolimbic dopamine system than the nigrostriatal sys-
tems in PD patients with PG.
The genetic of PG awaits for further independent studies. A few
studies investigated the role of genetic polymorphisms of the
dopaminergic system in PD with ICDs: DRD3 was found associated
with PG in PD, differently fromwhat observed in general population.
The next stepwould be to promote larger molecular genetic studies
addressing the issue of population stratiﬁcation, sample size, mul-
tiple testing and selection of genetic polymorphism. Actually,
stimulation of mesolimbic DRD3 receptors by DA is thought to un-
derlie the development of PG and possibly of other ICDs. The DA
effect seems tobe a class effect andnot speciﬁc for any particular DA.
The management of ICDs in PD is complex. Emerging data
suggest that reducing DA dose can improve PG symptoms over time
in PD patients. Other possible approaches include discontinuing or
switching DA therapy, reducing levodopa dose, and considering
alternative therapies such as atypical antipsychotics or DBS.
In conclusion, the present review supported the idea that PG can
be a side effect of DA therapy but also that a constellation of several
factors can contribute to develop this neuropsychiatric disturbance
in PD, as well as in general population. The association of PG with
behavioral disorders, cognitive impairments, and functional ab-
normalities in cortical and subcortical regions involved in ‘top-
down’ cognitive monitoring and inhibition of inappropriate be-
haviors are compatible with the idea that DA treatment can trigger
PG in susceptible PD patients with an imbalance of prefrontal-
subcortical limbic circuitries. In this perspective, it seems neces-
sary to identify different sub-phenotypes of PD to shed light on the
biological mechanisms that could render some PD patients
vulnerable to the development of PG secondary to the use of DA.References
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